Asthma inhaler showdown: generic vs. Brand-Name – study pulled before start

NCT ID NCT07223294

Terminated Disease control Sponsor: Sandoz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a generic version of the fluticasone furoate/vilanterol inhaler (Sandoz) works as well as the brand-name Breo Ellipta in adults with asthma. Participants would have stopped their usual asthma meds and used only the study inhaler or a placebo for 4 weeks. However, the study was withdrawn before any volunteers were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY

Contacts and locations

Locations

Sandoz Investigational Site

Cullman, Alabama, 35055, United States
Sandoz Investigational Site

Bradenton, Florida, 34208, United States
Sandoz Investigational Site

Leesburg, Florida, 34748, United States
Sandoz Investigational Site

Orlando, Florida, 32789, United States
Sandoz Investigational Site

St Louis, Missouri, 63141, United States
Sandoz Investigational Site

Raleigh, North Carolina, 27607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.